4D Molecular Therapeutics
OverviewSuggest Edit
4D Molecular Therapeutics is a biotechnology company focused on the creation of gene therapy products to cure genetic diseases. Its Therapeutic Vector Evolution platform enables to create adeno-associated virus (AAV) gene therapy vectors, which deliver genes to any diseased tissue or organ in the body.
| Type | Public | |
| Founded | 2013 | |
| HQ | Emeryville, CA, US | Map |
| Website | 4dmoleculartherapeutics.com |
Recent NewsAll News
- 4D Molecular Therapeutics Announces Pricing of Public Offering of Common Stock
- 4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease and Provides Clinical Data Update from the 4D-110 Phase 1/2 Clinical Trial in Patients with Choroideremia
- 4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150, a Dual-Transgene Intravitreal Gene Therapy for Patients with wet AMD
- 4D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data at the Upcoming ASRS Annual Meeting
Key People/Management at 4D Molecular Therapeutics
David Kirn
Chief Executive Officer, Co-Founder, President & Director
Robert Fishman
Chief Medical Officer
Peter Francis
Chief Scientific Officer, Ophthalmology Therapeutic Area Head
Theresa Janke
Chief Strategy Officer & Co-Founder
Fred Kamal
Chief Operating Officer & Chief Technical Officer
August Moretti
Chief Financial Officer
4D Molecular Therapeutics Office Locations
4D Molecular Therapeutics has an office in Emeryville
Emeryville, CA, US (HQ)
5858 Horton St #455
4D Molecular Therapeutics Financials and Metrics
4D Molecular Therapeutics Revenue
4D Molecular Therapeutics's revenue was reported to be $13.61 m in FY, 2020
| USD | |
|---|---|
Revenue (Q1, 2021) | 2.0m |
Net income (Q1, 2021) | (16.4m) |
EBIT (Q1, 2021) | (16.3m) |
Market capitalization (12-Nov-2021) | 668.5m |
Closing stock price (12-Nov-2021) | 25.0 |
Cash (31-Mar-2021) | 259.9m |
4D Molecular Therapeutics's current market capitalization is $668.5 m.
Annual
Half Year
Annual
Annual
| USD | FY, 2017 |
|---|---|
Financial Leverage | -1.4 x |
4D Molecular Therapeutics Revenue Breakdown
4D Molecular Therapeutics revenue breakdown by geographic segment: 90.0% from Switzerland, 9.5% from United States and 0.5% from Other
4D Molecular Therapeutics Online and Social Media Presence
143 Twitter followers
4D Molecular Therapeutics has 143 Twitter Followers. The number of followers has increased 0.7% month over month and increased 1.9% quarter over quarter
4D Molecular Therapeutics's Trends
4D Molecular Therapeutics News and Updates
October 29, 2021
4D Molecular Therapeutics Announces Pricing of Public Offering of Common Stock
EMERYVILLE, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced today that it priced an underwritten public offering of 4,750,000 shares of …
October 25, 2021
4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease and Provides Clinical Data Update from the 4D-110 Phase 1/2 Clinical Trial in Patients with Choroideremia
- First-ever clinical activity data reported on 4D-310 Fabry disease product candidate utilizing the proprietary C102 targeted and evolved vector invented through Therapeutic Vector Evolution
October 06, 2021
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150, a Dual-Transgene Intravitreal Gene Therapy for Patients with wet AMD
Initiation of 4D-150 Phase 1/2 clinical trial sites expected before year-end Initiation of 4D-150 Phase 1/2 clinical trial sites expected before year-end
September 24, 2021
4D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data at the Upcoming ASRS Annual Meeting
EMERYVILLE, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced a late-breaking presentation of preliminary clinical data from the on-going 4D-12…
June 24, 2021
4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial Clinical Safety and Tolerability Data for 4D-110 for Choroideremia and 4D-125 for XLRP, and Termination of Roche Collaboration and License Agreement
EMERYVILLE, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced an update on their rare disease ophthalmology product candidate portfolio includin…
June 03, 2021
4D Molecular Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
EMERYVILLE, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in the Goldman Sachs 42nd Annual Global Healthcar…
4D Molecular Therapeutics Blogs
May 18, 2021
A Targeted AAV Gene Therapy Product Candidate, 4D-310, for the Treatment of Fabry Disease: Intravenous Biodistribution, Transgene Expression & Safety in Non-Human Primates
Kevin Wittlesey, et al. Presented at the 24th Annual American Society of Gene & Cell Therapy (ASGCT) Meeting, May 11-14, 2021.
The post A Targeted AAV Gene Therapy Product Candidate, 4D-310, for the Treatment of Fabry Disease: Intravenous Biodistribution, Transgene Expression & Safety in Non…
May 14, 2021
A Multi-Mechanistic Anti-Angiogenic AAV Gene Therapy Product Candidate, 4D-150, for the Treatment of Wet Age-Related Macular Degeneration (Wet AMD) and Diabetic Macular Edema (DME): Intravitreal Biodistribution, Transgene Expression, Safety and Efficacy in Non-Human Primates
Peter Francis, et al. Presented at the 24th Annual American Society of Gene & Cell Therapy (ASGCT) Meeting, May 11-14, 2021.
The post A Multi-Mechanistic Anti-Angiogenic AAV Gene Therapy Product Candidate, 4D-150, for the Treatment of Wet Age-Related Macular Degeneration (Wet AMD) and Diabetic M…
May 07, 2021
Identification and Characterization of a Novel AAV Capsid & Product for the Treatment of Cystic Fibrosis Lung Disease
Melissa A. Calton, et al. Presented at the American Thoracic Society (ATS) 2021 Virtual Conference, May 14-19, 2021.
The post Identification and Characterization of a Novel AAV Capsid & Product for the Treatment of Cystic Fibrosis Lung Disease appeared first on 4D Molecular Therapeutics.
December 03, 2020
4D Molecular Therapeutics Strengthens Leadership Team with Key Appointments in Clinical Research and Development
Emeryville, CA – December 2, 2020 – 4D Molecular Therapeutics (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that Robert Fishman, M.D. has joined as Chief Medical Officer & Therapeutic Area Head, Pulmonology; Raphae…
November 18, 2020
4D Molecular Therapeutics Appoints Nancy Miller-Rich and Shawn Tomasello to its Board of Directors
Emeryville, CA – November 18, 2020 – 4D Molecular Therapeutics (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced the appointment of Nancy Miller-Rich and Shawn Tomasello to the Board of Directors. Nancy Miller-Rich brings …
4D Molecular Therapeutics Frequently Asked Questions
When was 4D Molecular Therapeutics founded?
4D Molecular Therapeutics was founded in 2013.
Who are 4D Molecular Therapeutics key executives?
4D Molecular Therapeutics's key executives are David Kirn, Robert Fishman and Peter Francis.
How many employees does 4D Molecular Therapeutics have?
4D Molecular Therapeutics has 78 employees.
What is 4D Molecular Therapeutics revenue?
Latest 4D Molecular Therapeutics annual revenue is $13.6 m.
What is 4D Molecular Therapeutics revenue per employee?
Latest 4D Molecular Therapeutics revenue per employee is $174.5 k.
Who are 4D Molecular Therapeutics competitors?
Competitors of 4D Molecular Therapeutics include Vertex Pharmaceuticals, Intellia Therapeutics and Verogen.
Where is 4D Molecular Therapeutics headquarters?
4D Molecular Therapeutics headquarters is located at 5858 Horton St #455, Emeryville.
Where are 4D Molecular Therapeutics offices?
4D Molecular Therapeutics has an office in Emeryville.
How many offices does 4D Molecular Therapeutics have?
4D Molecular Therapeutics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies